IMMX Immix Biopharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1873835 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-96.3%
TTM EPS YoY-7.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-26.9%
ROA-25.3%
ROIC (approx.)-1,121.6%
Asset turnover—
Leverage & solvency
Liabilities / assets3.1%
Debt / equity0.00x
Current ratio33.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $5.54M | $5.33M | $5.98M | $5.73M | $4.58M | $3.97M | $1.98M | $1.37M |
| SG&A expense | $10.40M | $7.12M | $4.82M | $5.17M | $3.08M | $2.75M | $2.71M | $3.61M |
| Operating income | -$15.95M | -$12.46M | -$10.80M | -$10.89M | -$7.66M | -$6.72M | -$4.68M | -$4.99M |
| Pretax income | -$13.93M | -$11.54M | -$10.09M | -$10.68M | -$7.58M | -$6.61M | -$4.53M | -$4.80M |
| Income tax | $0 | $14,322 | — | $11,266 | $7,722 | $8,914 | $9,822 | $10,785 |
| Net income | -$13.93M | -$11.56M | -$10.09M | -$10.69M | -$7.59M | -$6.62M | -$4.54M | -$4.81M |
| EBITDA | -$15.85M | -$12.37M | -$10.71M | -$10.84M | -$7.57M | -$6.66M | -$4.64M | -$4.97M |
| EPS (basic) | -0.19 | -0.18 | -0.18 | — | -0.24 | -0.22 | -0.15 | — |
| EPS (diluted) | -0.19 | -0.18 | -0.18 | — | -0.24 | -0.22 | -0.15 | — |
| Weighted avg. shares (diluted) | 74.09M | 63.77M | 55.37M | — | 31.93M | 29.98M | 29.70M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $320.32M | $225.49M | $79.25M | $93.93M | $15.95M | $11.64M | $15.92M | $17.68M |
| Short-term investments | $15.99M | $6.62M | $11.33M | $6.48M | — | — | — | — |
| Current assets | $338.08M | $233.79M | $92.27M | $101.24M | $16.58M | $12.33M | $16.78M | $20.20M |
| PP&E, net | $2.41M | $2.36M | $2.43M | $2.52M | $2.36M | $2.23M | $2.12M | $1.74M |
| Total assets | $345.95M | $239.11M | $95.82M | $104.84M | $20.08M | $15.64M | $19.89M | $22.95M |
| Current liabilities | $10.03M | $9.30M | $10.54M | $10.11M | $10.85M | $10.01M | $9.31M | $8.69M |
| Total liabilities | $10.89M | $10.19M | $11.45M | $11.04M | $11.82M | $10.98M | $10.30M | $9.70M |
| Shareholders' equity | $335.06M | $228.92M | $84.36M | $93.80M | $8.26M | $4.65M | $9.59M | $13.25M |
| Shares outstanding | 83.81M | 71.54M | 53.01M | 52.95M | 33.04M | 28.41M | 27.85M | 27.54M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.31M | -$11.74M | -$9.83M | -$11.03M | -$5.91M | -$5.31M | -$1.69M | -$1.48M |
| Capital expenditure | $121,241 | $21,043 | $32,486 | $165,126 | $372,456 | $127,630 | $67,713 | $507,151 |
| Free cash flow | -$12.43M | -$11.76M | -$9.86M | -$11.19M | -$6.28M | -$5.44M | -$1.75M | -$1.98M |
| Investing cash flow | -$12.03M | $2.67M | -$4.80M | -$6.65M | -$372,456 | -$127,630 | -$67,713 | -$507,151 |
| Financing cash flow | $119.17M | $155.28M | -$37,561 | $95.67M | $10.61M | — | — | $0 |
| Depreciation & amortization | $94,293 | $90,993 | $91,577 | $52,114 | $96,986 | $58,494 | $38,153 | $20,603 |
| Stock-based compensation | $0 | $978,140 | $575,565 | $570,796 | $470,471 | $532,249 | $868,359 | $705,653 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.